Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis Moves CSU Drug into Phase III After It Outperforms Company’s Own Product

Novartis is taking a treatment for persistent hives into Phase III trials after a mid-stage trial showed that the medication, ligelizumab (QGE031), outperformed Xolair in patients with chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.

Read More »

J&J-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

Read More »

Revance’s Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc’s blockbuster Botox passed a late-stage study, putting drug developer Revance Therapeutics Inc. on course to file for U.S. marketing approval in 2019.

Read More »

Roche says Hemlibra effective in pivotal study

Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of hemophilia, the Swiss drugmaker said.

Read More »

RedHill’s antibiotic succeeds in late-stage study

RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

Read More »

New Report Expresses Optimism Over Current State of Alzheimer’s Drug Development

Noting that from 1998 to 2017 there were about 146 failed shots at developing drugs for Alzheimer’s disease, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report on the state of the industry.

Read More »

Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails in Phase IIa Trial

Dynavax Technologies shares fell more than 5 percent after the company reported that an asthma drug being jointly developed with AstraZeneca failed to meet endpoints in a mid-stage trial.

Read More »

Alkermes schizophrenia drug keeps weight gain side effect in check

Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.

Read More »

AbbVie’s Mavyret Shows Sky-High Hep C Cure Rates

Chicago-based AbbVie announced new data for Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.

Read More »

Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Merck & Co.’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom